In addition to HCC, it would be interesting to see whether RNase1 is a potential biomarker to predict patient outcomes in other malignancies, especially in the cancer types including breast cancer23, esophageal squamous cell carcinoma, lung squamous cell carcinoma, stomach adenocarcinoma and thymoma which have significantly correlation between RNase1 and poor prognosis according to KM plotter analyses results (Supplementary Fig. 1f). This evidence concerns the gene RNASE1 and hepatocellular carcinoma.